IGF-1 LR3

IGF-1 LR3 is a modified analog of human insulin-like growth factor-1 engineered to circulate longer and act more consistently than native IGF-1. The protocol describes two key structural changes—an N-terminal extension and a substitution at position 3—that reduce binding to IGF-binding proteins. With less sequestration by binding proteins, the peptide remains bioavailable for longer, extending its effective half-life from minutes (native IGF-1) to several hours and supporting more stable exposure across the day. Functionally, IGF-1 LR3 signals through the IGF-1 receptor, a pathway linked in research to anabolic signaling, protein synthesis, cellular growth processes, and metabolic regulation. Because IGF signaling has insulin-like actions, the page emphasizes that glucose effects are a central safety consideration and that responses can be dose- and duration-dependent in research settings.